{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:20:09Z","timestamp":1790792409178,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872752"],"award-info":[{"award-number":["81872752"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bmc.2019.115178","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T08:55:12Z","timestamp":1573462512000},"page":"115178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent \u03b22-adrenoceptor agonists"],"prefix":"10.1016","volume":"28","author":[{"given":"Ce","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Yiu-Ho","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maosheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.115178_b0005","unstructured":"Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014. Available from www.goldcopd.org."},{"key":"10.1016\/j.bmc.2019.115178_b0010","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. http:\/\/goldcopd.org\/gold-2017-global-strategy-diagnosis-management-prevention-copd\/. Accessed January 13, 2017."},{"key":"10.1016\/j.bmc.2019.115178_b0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nri2254","article-title":"Immunology of asthma and chronic obstructive pulmonary disease","volume":"8","author":"Barnes","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmc.2019.115178_b0020","unstructured":"World Health Organization COPD Fact Sheet. 2016 [cited 2017 Feb18]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs315\/en\/."},{"key":"10.1016\/j.bmc.2019.115178_b0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1183\/09031936.06.00001306","article-title":"Impact of smoke-free workplace legislation on exposures and health: possibilities for prevention","volume":"28","author":"Jaakkola","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bmc.2019.115178_b0030","doi-asserted-by":"crossref","unstructured":"PLoS Medicine Editors. Are we publishing \u201cthe right stuff\u201d?. PLoS Med. 2006; 3: e512.","DOI":"10.1371\/journal.pmed.0030512"},{"key":"10.1016\/j.bmc.2019.115178_b0035","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1021\/jm801016j","article-title":"Synthesis and structure-activity relationships of long-acting \u03b22-adrenoceptor agonists incorporating arylsulfonamide groups","volume":"52","author":"Panayiotis","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115178_b0040","first-page":"225","article-title":"Efficacy of inhaled corticosteroids in asthma","volume":"15","author":"Branes","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bmc.2019.115178_b0045","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1517\/13543784.2012.710602","article-title":"An update on bronchodilators in Phase I and II clinical trials","volume":"21","author":"Cazzola","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmc.2019.115178_b0050","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.drudis.2013.07.005","article-title":"Novel anti-cholinergics in COPD","volume":"18","author":"Prakash","year":"2013","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.bmc.2019.115178_b0055","unstructured":"Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised 2013). Available at: www.goldcopd.org."},{"key":"10.1016\/j.bmc.2019.115178_b0060","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2174\/0929867311320120003","article-title":"Long-acting beta-agonists and their association with inhaled corticosteroids in COPD","volume":"20","author":"Fuso","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2019.115178_b0065","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1183\/09031936.97.10112489","article-title":"Inhaled dry-powder formoterol and salmeterol in asth-matic patients: onset of action, duration of effect and potency","volume":"10","author":"Palmqvist","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bmc.2019.115178_b0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1517\/14656566.2012.674513","article-title":"Indacaterol: a new long-acting \u03b22-agonist in the management of chronic obstruc-tive pulmonary disease","volume":"13","author":"Steiropoulos","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmc.2019.115178_b0075","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1021\/jm100068m","article-title":"The identification of indacaterol as an ultra long-acting inhaled beta 2 -adrenoceptor agonist","volume":"53","author":"Baur","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115178_b0080","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1080\/14656566.2018.1518431","article-title":"Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review","volume":"19","author":"Melani","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmc.2019.115178_b0085","unstructured":"FDA Olodaterol Approval Information. 2014 novel drug report.cited 2017 Jan. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/203108s000lbl.pdf."},{"key":"10.1016\/j.bmc.2019.115178_b0090","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.bmc.2018.10.043","article-title":"Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent \u03b22-adrenoceptor agonists","volume":"27","author":"Xing","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2019.115178_b0095","article-title":"Method for producing betamimetics","author":"Krueger","year":"2007","journal-title":"WO 2007020227A"},{"key":"10.1016\/j.bmc.2019.115178_b0100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0014-2999(96)00648-6","article-title":"Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors","volume":"315","author":"Sato","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2019.115178_b0105","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1164\/ajrccm.158.supplement_2.13tac110","article-title":"The \u03b2-adrenoceptor","volume":"158","author":"Johnson","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bmc.2019.115178_b0110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nature12572","article-title":"Adrenaline-activated structure of \u03b22-adrenoceptor stabilized by an engineered nanobody","volume":"502","author":"Ring","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.115178_b0115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1248\/bpb.26.323","article-title":"Trachea relaxing effects and \u03b22-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits","volume":"26","author":"Gan","year":"2003","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bmc.2019.115178_b0120","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejmech.2018.04.041","article-title":"Synthesis and biological evaluation of \u03b22-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold","volume":"152","author":"Ge","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.115178_b0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bioorg.2018.04.017","article-title":"Synthesis, biological evaluation and molecular modeling of 2-amino-2-phenylethanol derivatives as novel \u03b22-adrenoceptor agonists","volume":"79","author":"Ge","year":"2018","journal-title":"Bioorg Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619314750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619314750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:08:16Z","timestamp":1760836096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089619314750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0968089619314750"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115178","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent \u03b22-adrenoceptor agonists","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115178"}}